One of the leading companies in glycobiology, expands its management team and named Henner Kollenberg as Managing Director and Chief Financial Officer (CFO) as of March 2014.
Mr. Kollenberg brings more than 16 years of experience in general management, strategic planning and finance to the Company. Previously, he was Investment Director at Eckert Life Science Accelerator GmbH (ELSA). Before this, he worked as Managing Partner at Qonsult Group, a European consulting group, where he built up the Merger & Acquisitions and Private Equity units with a focus on technology-driven investments. For leading private equity funds Mr. Kollenberg advised portfolio companies through the entire investment life cycle, including deal sourcing, performance improvement and value creation, until the exit. He started his career in the corporate strategy department of Stinnes AG, one of Europe’s largest freight transportation and logistics providers. Mr. Kollenberg studied Economics at the University of Bonn (Diplom-Volkswirt) and earned a Master’s degree in Law & Economics (EMLE) from Stockholm University.
“Mr. Kollenberg has an exceptional track record in financing and managing fastgrowing and dynamic companies with valuable experience in the M&A field and this expansion of the management team is an important next step in developing our company,” said Dr. Steffen Goletz, CEO, CSO and founder of Glycotope. “His understanding and knowledge of general management, planning and finance will be particularly important at this time, when Glycotope is accelerating its growth through a broad portfolio of drug candidates in later stage clinical development,” added Dr. Franzpeter Bracht, who held the CFO function next to his function as COO.
“I am very pleased to join Glycotope at this exciting point in its journey,” said Henner Kollenberg.
“The Company has evolved into one of Germany’s largest independent biotech companies and I am very much looking forward to embarking on its next phase of growth and joining this proven and dynamic management team.”
Glycotope specializes in the glycosylation of proteins and is one of Germany’s largest independent biotech companies. Glycotope has a broad portfolio of drugs in clinical development, including the new cancer drugs, PankoMab-GEX™ and CetuGEX™, both in Phase IIb trials, and TrasGEX™, which has successfully completed its Ph I/IIa trial, as well as its improved fertility hormone, FSH-GEX™, which is expected to begin two Phase III clinical trials in 2014. In addition, the Company owns various antibody and non-antibody biopharmaceutical candidates in preclinical development. All products were glycooptimized, fully human glycosylated and produced with exceptional quality, reproducibility and yields using the validated GlycoExpress™ (GEX™) technology. This innovative technology enables Glycotope to increase the effectiveness, tolerability and affordability of a large number of drugs and expands their patient populations and indications.
Founded in 2001 on the Campus of the Max-Delbrück-Center for Molecular Medicine in Berlin-Buch, Glycotope now has more than 180 employees at two locations in Berlin and Heidelberg and covers the entire workflow from discovery, molecule optimization, clone and process development, preclinical and clinical drug development including GMP production. The Company’s investors include Munichbased Jossa Arznei GmbH (Strüngmann Group) and ELSA GmbH (Eckert Life Science Accelerator) in Berlin, which have provided total financing in excess of EUR 130 million.